The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.  The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.  The EC based its approval on a six-week trial of 316 adolescent patients, which evaluated the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!